The 340B Program in 2026: Congress, Courts, and Rebates

340B is in one of its most active policy periods in a decade, with legislation, litigation, and manufacturer policy all moving at once. In this episode of The Strategic Dose, host Lesley Pink is joined by Amanda Smith, counsel at K&L Gates, and Abel Haile, our VP of Health System Strategy and Commercial Analytics, to sort out what it all means for covered entities.The conversation covers the debate over how 340B should work rather than whether it should exist, why the undefined "patient" is the thread running through nearly every proposal, the arc of manufacturer restrictions since 2020, and HRSA's revised rebate model pilot scheduled for January 1, 2027. Amanda and Abel also look ahead to OPPS reimbursement and the growing role of state-level action, from contract pharmacy protection laws to prescription drug affordability boards.Recorded August 12, 2026. This space is moving quickly, so check current status on anything still in play.